(VIANEWS) – Shares of CARASENT (CARA.OL) saw their share price climb 28.18% at 15:37 EST Wednesday afternoon, following two consecutive sessions of gains and an Oslo Bors Benchmark Index_GI rise of 0.75% over four sessions that saw it close below 1,349.88; suggesting an upward trend in trading. CARASENT’s previous close was 11.00; 53.49% lower than its 52-week high of KR23.65
About CARASENT
Carasent ASA is an innovative provider of cloud-based electronic health record (EHR) solutions for the healthcare industry, serving clients throughout Sweden, Norway and internationally. Carasent provides innovative products and platform services across a range of healthcare segments, such as mid-to-large-sized organizations, occupational care services, specialist healthcare services and rehabilitation. Webdoc offers an expansive suite of solutions, such as Metodika EPM, Medrave M4, Health Profile Institute AB (HPI), Ad Curis, Ad Opus as well as additional platform services like Vardrummet Confrere Ad Voca electronic letters SMS services portal to medical services consulting services etc. Carasent’s dedication to providing high-quality EHR solutions and exceptional customer service have established it as a reliable partner of healthcare providers worldwide. Established in 1997 and headquartered in Oslo, Norway, Carasent ASA (formerly Apptix ASA) changed names in May 2019.
Yearly Analysis
Investment Perspective | CARESENT’s current share price of kr14.10 represents an attractive value compared to its 52-week high of kr23.65 and offers investors potential returns. Furthermore, CARESENT still remains above its 52-week low of kr13.50 which makes for an interesting prospectus. Expected sales growth of 30.3% this year and 18.1% next year bodes well for revenue at this company, and its EBITDA figure of 2.54 indicates profitability. Before investing, investors should carefully evaluate all possible risks and rewards before making decisions about CARASENT investments. Potential risks should also be carefully researched prior to any decisions being made; professional advice from financial professionals might also prove valuable before investing.
Technical Analysis
CARASENT (OTC: CARAY) stock has been on an overall downward trajectory, falling well below both its 50-day moving average of kr15.55 and 200-day moving average of kr16.10. Nevertheless, trading volume increased dramatically with today’s reported volume reaching 646,708, nearly five hundred percent higher than its average volume of 102,587.
The stochastic oscillator, an indicator used to gauge overbought and oversold conditions, indicates that CARASENT stock may currently be oversold (=20), which may provide investors with an opportunity for purchase; oversold stocks often experience a price rebound after experiencing significant sell-off.
Investors should exercise extreme caution when making investment decisions, taking into account factors like CARASENT’s financial health, industry trends and overall market conditions before making their final choice whether or not to purchase CARASENT stock.
Quarter Analysis
Sales Growth
CARASENT recently posted an impressive sales growth rate of 32.3% during its current quarter, marking an encouraging development in its performance. This far exceeds industry norms of 5-15% annualized sales increases.
Growth Estimates Quarters
Our company’s estimated quarterly growth estimates are negative 62.5% and negative 83.3%, which may seem dismal; however, keep in mind that growth estimates can change with new information becoming available.
CARASENT has experienced year-on-year quarterly revenue growth of 35.8% over the last twelve months, which indicates a substantial surge in earnings over this period. Now with total revenue reaching 227.09M, it has proven its ability to sustain consistent revenue expansion.
Investment Outlook
CARASENT’s strong sales growth and revenue expansion indicates its favorable performance; however, investors should take note of its negative growth estimates over the next two quarters which could negatively affect its financial performance in the short-term. As an investor, it’s best to monitor CARASENT closely in the coming months in order to make an informed investment decision.
Equity Analysis
Based on this information, CARASENT currently boasts an EPS for its most recent 12-month period of kr-0.6 – meaning its earnings per share was negative over that time period, suggesting the company may not be creating profits for shareholders.
ROE for the 12-trailing months stands at negative -4.05%, an indicator of whether the company may not be making optimal use of shareholder equity to generate profits. A negative ROE indicates ineffective use of equity by management in creating profits.
Overall, these financial metrics suggest that CARASENT may not be performing optimally in terms of profitability, which should be of concern for potential investors. Before making investment decisions it is critical that potential investors carefully assess a company’s financial health and performance.
More news about CARASENT (CARA.OL).
